Guard Therapeutics has announced that Peter Gilmour has been appointed Head of Preclinical Science. He has extensive experience in drug discovery and clinical drug development from leading positions at global pharmaceutical companies. Peter Gilmour will be part of the company's management team and will take up his post on 1 August 2020. Peter Gilmour, Ph.D., has a solid scientific background in experimental pharmacology, molecular biology and toxicology. He has a total of 25 years of experience in drug development from the global pharmaceutical companies Astellas and AstraZeneca. As project manager, he has participated in developing treatments in both cardiovascular, renal and respiratory diseases and has contributed to a number of approved patents.